Mylan Completes Acquisition of Certain Businesses from Famy Care to Create a Leading Women's Healthcare Franchise
Mylan has successfully completed the acquisition of certain women's healthcare businesses, now known as Jai Pharma, which were spun off from Famy Care Limited.
Nov. 20, 2015
/PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its subsidiary, Mylan Laboratories Limited, has successfully completed the acquisition of certain women's healthcare businesses, now known as Jai Pharma, which were spun off from Famy Care Limited. The transaction brings Mylan a broad women's care portfolio, strong technical capabilities and dedicated hormone manufacturing, which, when combined with Mylan's expansive global commercial footprint and supply chain infrastructure, will create a leading women's healthcare franchise.
commented, "The completion of this transaction is an important milestone as we continue to grow our global women's healthcare franchise, and take another step in our mission to provide the world's 7 billion people access to high quality medicine. In addition to strengthening our women's healthcare offering in
, we will continue to leverage our powerful commercial platform in
, now enhanced through our recent
deal, to serve this important therapeutic area.
"Moreover, we look forward to building upon our existing commercial presence in emerging markets by leveraging our global supply chain and operational excellence to further accelerate our growth. This will include building upon our existing women's care portfolio in
and expanding our reach in support of Family Planning 2020, a global partnership that aims to enable 120 million more women and girls to use contraceptives by 2020.
"We also are excited to welcome nearly 1,000 dedicated employees to our family and look forward to their contributions as we strive to create better health for a better world, one person at a time."
The acquisition is expected to be immediately accretive to Mylan's adjusted diluted earnings per share and Mylan's financial leverage is not materially altered as a result of this transaction.